By Michael Susin

 

AstraZeneca PLC said Friday that U.S.'s Food and Drug Administration has approved the use of its combined treatment Imfinzi with Imjud for the treatment of patients with metastatic lung cancer.

The Anglo-Swedish pharma major said the approval was based on phase three study results, which showed a significant survival benefit of Imjudo added to Imfinzi and chemotherapy.

The trials data showed that the treatment presented a 23% reduction in the risk of death when compared with a range of chemotherapy options, it said.

 

Write to Michael Susin at michael.susin@wsj.com

 

(END) Dow Jones Newswires

November 11, 2022 02:35 ET (07:35 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 12 2022 まで 1 2023 Astrazenecaのチャートをもっと見るにはこちらをクリック
Astrazeneca (LSE:AZN)
過去 株価チャート
から 1 2022 まで 1 2023 Astrazenecaのチャートをもっと見るにはこちらをクリック